Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and
Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy
young subjects and patients with Alzheimer Disease (AD).